

2022 CADTH Information Session

 Tuesday, April 5, 2022

 11:00 am to 3:30 pm EST

Register

After registering, you will receive a confirmation email with information about how to join the webinar.

Part 1

CADTH's 2022–2025 Strategic Plan

11:00 am. to 11:10 am

Welcome

Suzanne McGurn, President and CEO, CADTH

Stephen Lucas, Deputy Minister, Health Canada, Government of Canada

11:10 am to 11:35 am

Ahead of the Curve: Shaping Future-Ready Health Systems

David Agnew, Chair, CADTH Board of Directors

Suzanne McGurn, President and CEO, CADTH

11:35 am to 11:45 am

Responding to the New CADTH Strategic Plan

Jeannine Lagassé, Deputy Minister of Health & Wellness, Nova Scotia

Marney Paradis, Chair, CADTH Patient and Community Advisory Committee

Nicole DeKort, President, Medtech Canada

Pamela Fralick, President, Innovative Medicines Canada

11:50 am to 12:10 pm

Open Forum

The Open Forum is an opportunity for attendees to ask questions about the Strategic Plan.

12:10 pm

Part 1 Wrap Up

12:10 pm to 12:30 pm

Break

Part 2

Portfolio and Program Updates

12:30 pm to 12:35 pm

Welcome

Suzanne McGurn, President and CEO, CADTH

12:35 pm to 1:15 pm

Medical Device and Clinical Interventions Portfolio

An overview of recent and upcoming program updates, including Post-COVID, the Canadian Medical Imaging Inventory (CMII), future uses for the Technology Trends report; opportunities for input in upcoming assessments.

Lesley Dunfield, Vice-President, Medical Devices and Clinical Interventions, CADTH

Andra Morrison, Program Development Officer, CADTH

Gino De Angelis, Manager, Clinical Research, CADTH

1:15 pm to 1:55 pm

Pharmaceutical Reviews Portfolio

An overview of recent and upcoming program updates, including the transition of responsibility for systematic review and an update on CADTH's optimal use work.

Brent Fraser, Vice-President, Pharmaceutical Reviews, CADTH

Amanda Allard, Director, Pharmaceutical Reviews, CADTH

Peter Dyrda, Manager, Program and Policy Development, CADTH

1:55 pm to 2:10 pm

Break

2:10 pm to 3:05 pm

Other Initiatives and Updates

Post Market Drug Evaluation; Real World Evidence; Scientific Advice; Patient Engagement; Conflict of Interest

Tarry Ahuja, Director, Post Market Drug Evaluation (PMDE), CADTH

Nicole Mittmann, Chief Scientist and Vice-President, Evidence Standards, CADTH

Amy Sood, Manager, Scientific Advice, CADTH

Sarah Berglas, Manager, Patient Engagement, CADTH

Julia Thompson, Advisor, Corporate Risk, CADTH

3:05 pm to 3:30 pm

Open Forum

The Open Forum is an opportunity for attendees to ask questions the material presented during the session and, more broadly, about anything related to CADTH and its work.

3:30 pm

Part 2 Wrap Up
